Absci Corp Cash Flow Conversion Efficiency
Absci Corp cash flow conversion efficiency. Based on the latest financial reports, Absci Corp (ABSI) has a cash flow conversion efficiency ratio of -0.112x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.56 Million) by net assets ($246.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Absci Corp (2019–2025)
Cash flow conversion efficiency of Absci Corp from 2019 to 2025. This chart illustrates how Absci Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Absci Corp (ABSI) share price today for real-time trading data and today's change.
Absci Corp Cash Flow Conversion Ratio Explained
Absci Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Absci Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Absci Corp ranked by their cash flow conversion efficiency. Also see market value of Absci Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Concord Biotech Limited
NSE:CONCORDBIO
|
N/A |
|
Ultragenyx
NASDAQ:RARE
|
0.342x |
|
Eastern Communications Co Ltd A
SHG:600776
|
-0.006x |
|
Vestjysk Bank A/S
CO:VJBA
|
0.003x |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
0.022x |
|
DL E&C Co Ltd
KO:375500
|
0.027x |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
0.012x |
|
Changzheng Engineering Co Ltd
SHG:603698
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Absci Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Absci Corp from 2019 to 2025. Review ABSI free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.45 Million | $-92.92 Million | -0.491x | -21.36% |
| 2024-12-31 | $179.13 Million | $-72.40 Million | -0.404x | -10.17% |
| 2023-12-31 | $176.18 Million | $-64.64 Million | -0.367x | -23.78% |
| 2022-12-31 | $274.41 Million | $-81.34 Million | -0.296x | -79.08% |
| 2021-12-31 | $366.11 Million | $-60.60 Million | -0.166x | -1.10% |
| 2020-12-31 | $67.00 Million | $-10.97 Million | -0.164x | -211.71% |
| 2019-12-31 | $-41.16 Million | $-6.03 Million | 0.147x | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more